Boosting virus-based immune therapy for childhood medulloblastoma by targeting RNF2
Official title: Targeting RNF2 to Synergize with Oncolytic Immunovirotherapy to Induce Anti-Cancer Immunity in Medulloblastoma
Funded at University of Tx Md Anderson Can Ctr · NIH-11271139 · Data updated 2026-11-12
This project will try blocking a cancer protein called RNF2 to strengthen a virus-based immune treatment for children with medulloblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 1, 2026 |
| Project end | April 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $421,361 |
| NIH project number | 1R01NS146081-01 |
| Project ID | NIH-11271139 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children with medulloblastoma—especially those with recurrent disease or leptomeningeal spread—who can travel to and receive care at specialized cancer centers may be candidates for this work as it moves into clinical testing.
✕Less likely to help
Patients whose tumors do not rely on RNF2, who cannot tolerate viral-based therapies, or who are too medically frail for experimental treatment may not benefit from this approach.
What this research studies
From a patient's view, researchers are combining an engineered cancer-killing virus (G207) with methods to block a tumor protein called RNF2 to help the immune system stay active against medulloblastoma. Work will include lab and animal experiments to understand how RNF2 helps tumors escape immune attack and to test whether blocking it makes the virus therapy work better and longer. The team builds on prior safety results with G207 in pediatric brain tumors and will move promising combo approaches toward early clinical testing at specialized centers. The goal is to create a treatment that not only shrinks tumors but also keeps them from coming back by sustaining a strong anti-tumor immune response.
Why it matters
Potential benefit: If successful, this approach could produce safer, longer-lasting treatments that better control tumor spread and reduce the lifelong side effects children often face.
How similar studies have gone: Engineered oncolytic virus G207 has already shown safety and immune activation in pediatric brain tumor trials, but durable responses have been limited, making the RNF2 combination a newer strategy.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Friedman, Gregory K — University of Tx Md Anderson Can Ctr
- Study coordinator: Friedman, Gregory K
Related research
Other NIH-funded projects on the same topics.
-
Glial origins and signaling in childhood brain cancer (medulloblastoma)
A new study looks at how glial cells may drive relapse and growth in childhood medulloblastoma, with the goal of finding targeted treatments.
-
Next generation GPC2 CARs to treat pediatric medulloblastoma
A new CAR T-cell therapy approach targets a protein common on child brain tumor cells to improve outcomes for kids with medulloblastoma.
-
Targeting medulloblastoma with multispecific T-cell engagers
A pediatric brain cancer treatment study tests a new multi-targeted T-cell engager designed to reach brain tumors and help the immune system kill cancer cells.
-
Efflux-aware brain barrier model to guide pediatric medulloblastoma drug discovery
A study using a pediatric brain cancer model to test how radiation-activated digoxin-like compounds could safely reach brain tumors in children.
-
Overcoming medulloblastoma resistance in kids using in vivo perturb-seq and preclinical therapies
A patient-focused study aiming to find new, less toxic ways to treat pediatric medulloblastoma by using advanced genetic screening to identify effective drug targets in preclinical models.
-
Dysregulation of a key gene complex and its role in Group 4 medulloblastoma
A study explores how disruption of a core gene complex in brain development may drive Group 4 medulloblastoma and seeks to understand new ways to help affected children.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.